Original Article
Brief Report
Progressive Multifocal Leukoencephalopathy Complicating Treatment with Natalizumab and Interferon Beta-1a for Multiple Sclerosis
N Engl J Med 2005; 353:369-374July 28, 2005
- Abstract
A 46-year-old woman with relapsing–remitting multiple sclerosis died from progressive multifocal leukoencephalopathy (PML) after having received 37 doses of natalizumab (300 mg every four weeks) as part of a clinical trial of natalizumab and interferon beta-1a. PML was diagnosed on the basis of the finding of JC viral DNA in cerebrospinal fluid on polymerase-chain-reaction assay and was confirmed at autopsy. Nearly every tissue section from bilateral cerebral hemispheres contained either macroscopic or microscopic PML lesions. There was extensive tissue destruction and cavitation in the left frontoparietal area, large numbers of bizarre astrocytes, and inclusion-bearing oligodendrocytes, which were positive for JC virus DNA on in situ hybridization.
Media in This Article
Figure 1
MRI Findings (Panels A, B, and C) and Autopsy Findings (Panel D).Figure 2
Histologic and MRI Findings.Article Activity
- Article
Progressive multifocal leukoencephalopathy (PML), a demyelinating disease of the central nervous system (CNS), is associated with high rates of morbidity and mortality and occurs almost exclusively in immunocompromised patients.1 We describe a patient with multiple sclerosis who died of PML after receiving natalizumab (Tysabri, Biogen Idec) as part of a clinical trial conducted to test the safety and efficacy of natalizumab in combination with interferon beta-1a (Avonex, Biogen Idec) in the treatment of relapsing–remitting multiple sclerosis. To our knowledge, there have been no prior reports of the concomitant association of multiple sclerosis and PML.
Natalizumab is a humanized monoclonal antibody against α4 integrins that was recently introduced for the treatment of multiple sclerosis. The drug was withdrawn from the market after reports of the development of PML in two patients with multiple sclerosis who were receiving natalizumab and interferon beta-1a in clinical trials. An additional case of PML, in a patient receiving natalizumab for the treatment of Crohn's disease, is described elsewhere in this issue of the Journal.2
Case Report
A 41-year-old, right-handed woman began to have numbness and burning pain in her right foot and leg and tingling numbness and clumsiness in her right hand in June 1999. She had a history of migraine and transient numbness of the left hand. A neurologic examination revealed increased tone on her right side and generalized hyperreflexia (3+) with normal plantar responses. In September 1999, magnetic resonance imaging (MRI) with contrast medium showed four small, nonenhancing foci of increased signal in the corona radiata bilaterally on the fluid-attenuated inversion recovery (FLAIR) sequences. Electromyography and nerve-conduction studies showed no abnormalities. Six weeks later, her leg symptoms had improved, but the patient reported new visual blurring in her right eye. The visual acuity of the right eye was 20/100, and that of the left was 20/15. Examination of cerebrospinal fluid in November 1999 showed 1 white cell per cubic millimeter, 55 mg of protein per deciliter, and normal values for glucose (64 mg per deciliter [3.6 mmol per liter]), IgG (3.2 mg per deciliter), the IgG index (0.57), and the IgG-synthesis rate (0.3 mg per 24 hours). No oligoclonal bands were detected in a specimen of cerebrospinal fluid that was concentrated by a factor of 80. Levels of vitamin B12 and folate were normal, tests for antinuclear antibodies and anticentromere antibodies were negative, and thyroid-function tests were normal. A complete blood count was also normal, except for mild leukocytosis (11,200 cells per cubic millimeter).
In January 2000, MRI showed two new nonenhancing parietal lesions with increased FLAIR signal and decreased T1-weighted signal. In February 2000, the patient reported that her vision was normal and that her right-sided numbness had nearly resolved. She began receiving 30 μg of interferon beta-1a intramuscularly each week, tizanidine, calcium, magnesium, and vitamins B, C, and E for presumed multiple sclerosis (Table 1Table 1
Doses and Timing of Treatments for Multiple Sclerosis.). In May 2000, she began taking tamsulosin for difficulty with bladder emptying and citalopram for depression.In March 2001, the patient noted worsening vision, band-like paresthesias around her back and abdomen, and increasing weakness and spasticity of her legs. The strength of both legs was mildly decreased (4+/5), and her gait was slightly spastic, although her deep tendon reflexes were normal. She received 500 mg of methylprednisolone twice daily intravenously for five days (March 16 through 20, 2001) for a suspected exacerbation of multiple sclerosis. In September 2001, she reported some decline in fine motor skills in her hands and worsening spasticity in her legs as well as some decline in cognition, including short-term memory, and began taking donepezil. She had a score of 2.5 on the Kurtzke Expanded Disability Status Scale (EDSS) in March 2002 (range of scores, 0 to 10, with higher scores indicating a greater degree of disability).
In April 2002, the patient was enrolled in a randomized, placebo-controlled, parallel-group, multicenter study designed to determine the safety and efficacy of natalizumab combined with interferon beta-1a in patients with relapsing–remitting multiple sclerosis (the Biogen Idec and Elan 1802 SENTINEL trial). At the time of her enrollment, T2-weighted MRI showed approximately nine lesions and her EDSS score was 0. She continued to take 30 μg of interferon beta-1a intramuscularly weekly throughout the study. Additional medications at study entry included citalopram, rofecoxib, and tramadol in combination with acetaminophen.
During the study, the patient received a total of 30 doses of natalizumab (300 mg, or approximately 6 mg per kilogram of body weight, each) by intravenous infusion at four-week intervals between April 12, 2002, and July 9, 2004. She also received tizanidine, donepezil, and briefly, galantamine. In July 2004, she was enrolled in an open-label extension study (Biogen Idec/Elan 1808) and received seven additional 300-mg doses of natalizumab at four-week intervals, with the last dose given on January 18, 2005. No antibodies developed against either interferon beta-1a or natalizumab. Pharmacokinetic studies showed that the clearance of natalizumab in the patient (0.0136 liter per hour) was similar to the median value in the study population (0.0138 liter per hour). A follow-up T2-weighted MRI study in April 2003 showed five new or enlarging lesions. A similar study in April 2004 showed one new or enlarging lesion. No enhancing lesions were noted. Unfortunately, these MRI scans were not available for review, and the reports specified only the number of lesions, not the location. No clinical or suspected relapses of multiple sclerosis were identified, and the patient's EDSS score remained between 0 and 2 through July 2004.
In November 2004, the patient reported new problems with hand–eye coordination, including difficulty writing and typing, as well as problems with her speech. A mental-status examination performed at that time showed a decreased fund of information, minor errors on a drawing of a three-dimensional cube and on tests of mathematical skills, and reduced immediate recall on a word-learning test. Her cranial nerves were normal. Her strength was intact, but she had mildly increased tone in her legs and hyperactive (3+) reflexes bilaterally. In December 2004, right-sided numbness developed and word-finding difficulty increased. The patient had difficulty carrying on a conversation and became increasingly forgetful. A neurologic examination revealed difficulty with expressive speech, with preserved comprehension, some right–left confusion, irregular saccadic eye movements, and increased tone on her right side. She received methylprednisolone (500 mg intravenously twice daily) from December 15 through 19, 2004. An MRI study performed on December 15 showed a large area of increased T2-weighted and decreased T1-weighted signal in the left frontal lobe posteriorly involving the subcortical white matter and extending into the centrum semiovale and corona radiata, without enhancement or mass effect (Figure 1AFigure 1
MRI Findings (Panels A, B, and C) and Autopsy Findings (Panel D).). A second area of abnormal signal was noted in the right posterior parietal lobe. On December 29, 2004, a right-sided hemiparesis with an extensor plantar response was noted.On January 5, 2005, the patient's condition was judged to be worse, with increasing right-sided hemiparesis and worsening nonfluent aphasia. Her right-arm strength was 0/5, and her right-leg strength was 2/5 proximally and 0/5 distally. On the assumption that her clinical deterioration represented an exacerbation of multiple sclerosis, she received another five-day course of methylprednisolone, beginning on January 5, 2005 (500 mg intravenously twice daily). Her last dose of natalizumab was given on January 18, 2005. On January 24, 2005, her white-cell count was 14,400 per cubic millimeter (77 percent neutrophils, 18 percent lymphocytes, 4 percent monocytes, and 1 percent eosinophils), with an absolute lymphocyte count of 2500 per cubic millimeter.
The patient's neurologic status continued to decline, and she was hospitalized on February 12, 2005. On admission, she was unresponsive, with a right-sided gaze preference. She had a marked spastic right-sided hemiplegia and some left-sided weakness. An MRI scan obtained on February 12 (Figure 1B and Figure 1C) showed a dramatic increase in the extent of the high T2-weighted and low T1-weighted signal abnormalities in the left hemisphere, with extension of the lesion to the frontal, parietal, and temporal lobes and across the corpus callosum to the right frontal lobe. New midbrain and pontine lesions were also present. There was no enhancement or mass effect. At admission, the patient had a white-cell count of 14,000 per cubic millimeter (77 percent neutrophils, 16 percent lymphocytes, 6 percent monocytes, and 1 percent eosinophils and basophils). Her absolute lymphocyte count was normal (2300 cells per cubic millimeter).
An examination of cerebrospinal fluid on February 14, 2005, revealed the following values: 53 mg of protein per deciliter, 90 mg of glucose per deciliter (5.0 mmol per liter), 4.3 mg of IgG per deciliter, an IgG index of 0.49, a ratio of IgG to albumin of 0.08, and an IgG-synthesis rate of 1.78 mg per 24 hours. No oligoclonal bands were noted. The results of Gram's staining of a cerebrospinal fluid sample were unremarkable. A polymerase-chain-reaction (PCR) assay of cerebrospinal fluid for herpes simplex virus was negative, as were tests for West Nile virus IgG and IgM, eastern equine encephalomyelitis virus IgG and IgM, Borrelia burgdorferi IgG and IgM, and cryptococcal antigen and stains and cultures for bacteria, fungi, and acid-fast bacilli. A test for serum antibody against human immunodeficiency virus (HIV) type 1 and 2 was nonreactive. CD4+ and CD8+ T-cell counts were not assessed, but at no time was either absolute or relative lymphopenia noted.
The treating neurologist suspected PML, and a cerebrospinal fluid sample sent to the Mayo Medical Laboratories (Rochester, Minn.) for JC virus PCR testing was positive. The patient died on February 24, 2005; she was 46 years old.
Methods and Results
Postmortem examination showed bilateral aspiration pneumonia and cachexia. There was prominent sinus histiocytosis of the lymph nodes and possible depletion of CD8+ T cells in comparison with the levels of CD4+ T cells, probably owing to severe terminal debilitation. Examination of the bone marrow showed a clinically significant leftward shift in granulocytic maturation. All other systemic organs were histologically normal; no non-CNS opportunistic infections were found. Postmortem blood samples were not tested for JC virus DNA or antibody.
The formalin-fixed, 1140-g brain was fluctuant on palpation over a large portion of the anterior left hemisphere; no discoloration or meningeal opacification was present. On coronal sectioning, this softened area corresponded to massive, coalescent areas of severe cavitation involving most of the left frontoparietal white matter, leaving only a ribbon-like strip of intact overlying cortex (Figure 1D). Smaller, noncavitated, ovoid areas of discoloration, a typical feature of PML, studded the remaining left-hemispheric white matter, particularly at the junctions between cortical gray matter and white matter, and involved the right superior frontal gyrus (Figure 2AFigure 2
Histologic and MRI Findings.). A 7-mm lesion was identified in the left cerebral peduncle (Figure 2B and Figure 2C). No multiple-sclerosis plaques were discernible in the corona radiata.The brain stem, spinal cord, and optic chiasm were submitted in toto for histologic examination. Sections (total, 73 blocks) from the brain and spinal cord were stained with hematoxylin and eosin, with one fourth of the sections also stained with Luxol fast blue and periodic acid–Schiff for myelin. All sections were devoid of acute anoxic injury and vasculitis. Areas of PML showed near-total loss of myelin, an influx of macrophages, and numerous reactive astrocytes, but no perivascular or parenchymal lymphocytic inflammation (Figure 2D). Astrocytes with bizarre, enlarged hyperchromatic nuclei, a typical finding in PML, were common, even in smaller lesions (Figure 2D). There were large numbers of oligodendrocytes with the classic violaceous intranuclear inclusions of PML (Figure 2E). Cells with inclusions had a strong positive signal for JC virus DNA on in situ hybridization (probe 40847, Enzo Life Sciences) (Figure 2F).
In addition to the PML lesions seen on gross examination, myriad minute lesions were easily identified microscopically in virtually every section examined from the left cerebral hemisphere, as well as in most of the sections from the right side and all of the brain-stem sections. PML was found only focally in the cerebellum; no granule-cell depletion was seen. The optic nerve, chiasm, and spinal cord contained neither PML lesions nor multiple-sclerosis demyelinating lesions. Examination of the spinal cord showed unilateral wallerian degeneration that was due to the cavitated lesions involving the left motor strip and internal capsule. Remote cortical microinfarctions were found in the right superior frontal and parietal gyri and splenium of the corpus callosum.
Discussion
PML is a demyelinating disease of the CNS caused by lytic infection of oligodendrocytes by JC polyomavirus. Primary JC virus infection occurs in childhood and is asymptomatic. JC virus antibodies are detectable in approximately 50 to 70 percent of the adult population.3,4 After the primary infection, JC virus remains latent in kidneys and lymphoid organs. Up to 64 percent of healthy adults have shedding of JC virus in urine in the absence of any clinical symptoms, suggesting that asymptomatic active JC virus infection is common in immunocompetent persons.5 In contrast, PML occurs almost exclusively in immunocompromised persons, particularly those with depressed cell-mediated immunity resulting from HIV infection, hematologic cancers, or immunosuppressive medications.1 In recipients of bone marrow transplants, PML has also been associated with treatment with rituximab, an antibody against CD20 expressed on B cells,6 and cases of PML-like CNS demyelinating illness have been reported in patients with rheumatic diseases treated with antagonists of tumor necrosis factor α.7 Although multiple sclerosis is an immune-mediated disorder, to our knowledge, patients with multiple sclerosis have not previously been identified as at increased risk for PML.
Natalizumab is a humanized monoclonal antibody against α4 integrins that was approved by the Food and Drug Administration for the treatment of several immune-mediated disorders, including multiple sclerosis and inflammatory bowel disease.8-10 Antibodies against α4 integrins inhibit the binding of cells expressing α4β1 integrin and α4β7 integrin (e.g., lymphocytes) to vascular-cell adhesion molecule 1 and mucosal addressin-cell adhesion molecule 1 on endothelial cells, a critical step in the diapedesis of lymphocytes across blood vessels into the CNS and mucosal organs.10,11 Treatment with antibodies against α4 integrins prevents inflammatory cells from crossing the blood–brain barrier and inhibits the accumulation of immune cells in the CNS in animals with experimental allergic encephalomyelitis.11-13
Our patient received interferon beta-1a for nearly five years and received combined therapy with natalizumab and interferon beta-1a for just over two years as part of the SENTINEL trial. We therefore cannot rule out a potential contributory role of interferon beta-1a in the genesis of this patient's PML. However, to date, there have been no reported cases of PML in patients receiving interferon beta-1a monotherapy.
The diagnosis of PML was established on the basis of a positive PCR assay for JC viral DNA in cerebrospinal fluid in a patient with clinical and neuroimaging findings that were typical of PML, and the diagnosis was confirmed at autopsy. The severity and extent of disease were dramatic. Nearly every tissue section from bilateral cerebral hemispheres that we examined had either macroscopic or microscopic PML lesions, ranging from minute to massive in size. There was extensive tissue destruction and cavitation in the left frontoparietal area, and the lesions contained large numbers of oligodendrocytes with inclusions. No inflammatory response was present. Although no formal quantitation was performed, the extent of the PML involvement was similar to or exceeded that seen in HIV-infected patients before the advent of highly active antiretroviral therapy.
Dr. Tyler is supported by the Reuler–Lewin Family Professorship of Neurology.
This article was published at www.nejm.org on June 9, 2005.
We are indebted to the neurologist who cared for the patient; to Dr. Kate Dawson from Biogen Idec, for furnishing some additional clinical and laboratory information on the patient; to Ms. Lisa Litzenberger for her photographic expertise; to the histologic technicians, supervised by Mr. David Davis, for slide preparation; and to Ms. Cindy McNair for assistance in the preparation of the manuscript.
Source Information
From the Departments of Pathology (B.K.K.-D.), Neurology (B.K.K.-D., K.L.T.), Neurosurgery (B.K.K.-D.), Medicine (K.L.T.), Microbiology (K.L.T.), and Immunology (K.L.T.), University of Colorado Health Sciences Center; and the Denver Veterans Affairs Medical Center (K.L.T.) — both in Denver.
Address reprint requests to Dr. Kleinschmidt-DeMasters at the Department of Pathology, B-216, University of Colorado Health Sciences Center, 4200 E. 9th Ave., Denver, CO 80262.
- References
References
1
Koralnik IJ . New insights into progressive multifocal leukoencephalopathy. Curr Opin Neurol 2004;17:365-370
CrossRef | Web of Science | Medline2
Van Assche G ,Van Ranst M ,Sciot R , et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med 2005;353:362-368
Full Text | Web of Science | Medline3
Knowles WA ,Pipkin P ,Andrews N , et al. Population-based study of antibody to the human polyomaviruses BKV and JCV and the simian polyomavirus SV40. J Med Virol 2003;71:115-123
CrossRef | Web of Science | Medline4
Stolt A ,Sasnauskas K ,Koskela P ,Lehtinen M ,Dillner J . Seroepidemiology of the human polyomaviruses. J Gen Virol 2003;84:1499-1504
CrossRef | Web of Science | Medline5
Gasnault J ,Kahraman M , de Goer de Herve MG,Durali D ,Delfraissy JF ,Taoufik Y . Critical role of JC virus-specific CD4 T-cell responses in preventing progressive multifocal leukoencephalopathy. AIDS 2003;17:1443-1449
CrossRef | Web of Science | Medline6
Goldberg SL ,Pecora AL ,Alter RS , et al. Unusual viral infections (progressive multifocal leukoencephalopathy and cytomegalovirus disease) after high-dose chemotherapy with autologous blood stem cell rescue and peritransplantation rituximab. Blood 2002;99:1486-1488
CrossRef | Web of Science | Medline7
Imperato AK ,Bingham CO III ,Abramson SB . Overview of benefit/risk of biological agents. Clin Exp Rheumatol 2004;22:Suppl 35:S108-S114
Web of Science | Medline8
Miller DH ,Khan OA ,Sheremata WA , et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2003;348:15-23
Full Text | Web of Science | Medline9
Ghosh S ,Goldin E ,Gordon FH , et al. Natalizumab for active Crohn's disease. N Engl J Med 2003;348:24-32
Full Text | Web of Science | Medline10
Rice GPA ,Hartung H-P ,Calabresi PA . Anti-alpha4 integrin therapy for multiple sclerosis: mechanisms and rationale. Neurology 2005;64:1336-1342
CrossRef | Web of Science | Medline11
von Andrian UH ,Engelhardt B . α4 Integrins as therapeutic targets in autoimmune disease. N Engl J Med 2003;348:68-72
Full Text | Web of Science | Medline12
Yednock TA ,Cannon C ,Fritz LC ,Sanchez-Madrid F ,Steinman L ,Karin N . Prevention of experimental autoimmune encephalomyelitis by antibodies against α4β1 integrin. Nature 1992;356:63-66
CrossRef | Web of Science | Medline13
Kent SJ ,Karlik SJ ,Cannon C , et al. A monoclonal antibody to alpha 4 integrin suppresses and reverses active experimental allergic encephalomyelitis. J Neuroimmunol 1995;58:1-10
CrossRef | Web of Science | Medline
- Citing Articles (306)
Citing Articles
1
A. Bellizzi, C. Nardis, E. Anzivino, D. M. Rodìo, D. Fioriti, M. Mischitelli, F. Chiarini, V. Pietropaolo. (2012) Human polyomavirus JC reactivation and pathogenetic mechanisms of progressive multifocal leukoencephalopathy and cancer in the era of monoclonal antibody therapies. Journal of NeuroVirology
CrossRef2
Pelletier, Daniel, Hafler, David A., . (2012) Fingolimod for Multiple Sclerosis. New England Journal of Medicine 366:4, 339-347
Full Text3
Hartmut Wekerle, Alexander Flügel, Lars Fugger, Georg Schett, David Serreze. (2012) Autoimmunity's next top models. Nature Medicine 18:1, 66-70
CrossRef4
Shyi-Jou Chen, Yen-Ling Wang, Hueng-Chuen Fan, Wen-Tsung Lo, Chih-Chien Wang, Huey-Kang Sytwu. (2012) Current Status of the Immunomodulation and Immunomediated Therapeutic Strategies for Multiple Sclerosis. Clinical and Developmental Immunology 2012, 1-16
CrossRef5
Maria Chiara G Monaco, Eugene O Major. (2012) The link between VLA-4 and JC virus reactivation. Expert Review of Clinical Immunology 8:1, 63-72
CrossRef6
Anne Waschbisch, Tobias Derfuss. (2012) Placebo-controlled trials in relapsing–remitting multiple sclerosis: are they still needed?. Future Neurology 7:1, 37-44
CrossRef7
Henrik Gensicke, David Leppert, Özgür Yaldizli, Raija L.P. Lindberg, Matthias Mehling, Ludwig Kappos, Jens Kuhle. (2012) Monoclonal Antibodies and Recombinant Immunoglobulins for the Treatment of Multiple Sclerosis. CNS Drugs 26:1, 11-37
CrossRef8
Yukiko Shishido-Hara, Shizuko Ichinose, Toshiki Uchihara. (2012) JC Virus Intranuclear Inclusions Associated with PML Protein Nuclear Bodies. The American Journal of Pathology
CrossRef9
Saskia Thomas, Daniel C. Baumgart. (2011) Targeting leukocyte migration and adhesion in Crohn’s disease and ulcerative colitis. Inflammopharmacology
CrossRef10
Raquel Planas, Ilijas Jelc̆ić, Sven Schippling, Roland Martin, Mireia Sospedra. (2011) Natalizumab Treatment Perturbs Memory- and Marginal Zone-like B-cell Homing in Secondary Lymphoid Organs in Multiple Sclerosis. European Journal of Immunologyn/a-n/a
CrossRef11
E. Tavazzi, P. Ferrante, K. Khalili. (2011) Progressive multifocal leukoencephalopathy: an unexpected complication of modern therapeutic monoclonal antibody therapies. Clinical Microbiology and Infection 17:12, 1776-1780
CrossRef12
M. A. Sahraian, E.-W. Radue, A. Eshaghi, S. Besliu, A. Minagar. (2011) Progressive multifocal leukoencephalopathy: a review of the neuroimaging features and differential diagnosis. European Journal of Neurologyno-no
CrossRef13
I. Ifergan, H. Kebir, J. I. Alvarez, G. Marceau, M. Bernard, L. Bourbonniere, J. Poirier, P. Duquette, P. J. Talbot, N. Arbour, A. Prat. (2011) Central nervous system recruitment of effector memory CD8+ T lymphocytes during neuroinflammation is dependent on 4 integrin. Brain 134:12, 3557-3574
CrossRef14
Per Soelberg Sørensen. (2011) Balancing the benefits and risks of disease-modifying therapy in patients with multiple sclerosis. Journal of the Neurological Sciences 311, S29-S34
CrossRef15
Kerstin Hellwig, Ralf Gold. (2011) Progressive multifocal leukoencephalopathy and natalizumab. Journal of Neurology 258:11, 1920-1928
CrossRef16
Eugenio Pucci, Giorgio Giuliani, Alessandra Solari, Silvana Simi, Silvia Minozzi, Carlo Di Pietrantonj, Ian Galea, Eugenio Pucci. 2011. Natalizumab for relapsing remitting multiple sclerosis. .
CrossRef17
Jérôme TJ Nicol, Antoine Touzé. (2011) Prevalence of polyomaviruses and links with human diseases. Future Virology 6:10, 1187-1197
CrossRef18
L. Aly, S. Yousef, S. Schippling, I. Jelcic, P. Breiden, J. Matschke, R. Schulz, S. Bofill-Mas, L. Jones, V. Demina, M. Linnebank, G. Ogg, R. Girones, T. Weber, M. Sospedra, R. Martin. (2011) Central role of JC virus-specific CD4+ lymphocytes in progressive multi-focal leucoencephalopathy-immune reconstitution inflammatory syndrome. Brain 134:9, 2687-2702
CrossRef19
Gillian M. Bell, Gary Reynolds, John D. Isaacs. (2011) Biologic therapies in non-rheumatic diseases: lessons for rheumatologists?. Nature Reviews Rheumatology 7:9, 507-516
CrossRef20
Anna Bellizzi, Elena Anzivino, Federica Ferrari, Giovanni Nardo, Maria Teresa Colosimo, Daniela Fioriti, Monica Mischitelli, Fernanda Chiarini, Salvatore Cucchiara, Valeria Pietropaolo. (2011) Polyomavirus JC reactivation and noncoding control region sequence analysis in pediatric Crohn's disease patients treated with infliximab. Journal of NeuroVirology 17:4, 303-313
CrossRef21
Per Soelberg Sorensen, Jan Lycke, Juha-Pekka Erälinna, Astrid Edland, Xingchen Wu, Jette Lautrup Frederiksen, Annette Oturai, Clas Malmeström, Egon Stenager, Finn Sellebjerg, Helle Bach Sondergaard. (2011) Simvastatin as add-on therapy to interferon beta-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial. The Lancet Neurology 10:8, 691-701
CrossRef22
Ludwig Kappos, David Bates, Gilles Edan, Mefkûre Eraksoy, Antonio Garcia-Merino, Nikolaos Grigoriadis, Hans-Peter Hartung, Eva Havrdová, Jan Hillert, Reinhard Hohlfeld, Marcelo Kremenchutzky, Olivier Lyon-Caen, Ariel Miller, Carlo Pozzilli, Mads Ravnborg, Takahiko Saida, Christian Sindic, Karl Vass, David B Clifford, Stephen Hauser, Eugene O Major, Paul W O'Connor, Howard L Weiner, Michel Clanet, Ralf Gold, Hans H Hirsch, Ernst-Wilhelm Radü, Per Soelberg Sørensen, John King. (2011) Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring. The Lancet Neurology 10:8, 745-758
CrossRef23
C. E. Reid, H. Li, G. Sur, P. Carmillo, S. Bushnell, R. Tizard, M. McAuliffe, C. Tonkin, K. Simon, S. Goelz, P. Cinque, L. Gorelik, J. P. Carulli. (2011) Sequencing and Analysis of JC Virus DNA From Natalizumab-Treated PML Patients. Journal of Infectious Diseases 204:2, 237-244
CrossRef24
A. Horga, M. Tintoré. (2011) Natalizumab para la esclerosis múltiple remitente-recurrente. Neurología 26:6, 357-368
CrossRef25
Brian S Sheridan, Leo Lefrançois. (2011) Regional and mucosal memory T cells. Nature Immunology 131:6, 485-491
CrossRef26
Mario Skarica, Christopher Eckstein, Katharine A. Whartenby, Peter A. Calabresi. (2011) Novel mechanisms of immune modulation of natalizumab in multiple sclerosis patients. Journal of Neuroimmunology 235:1-2, 70-76
CrossRef27
Joseph R Berger. (2011) The basis for modeling progressive multifocal leukoencephalopathy pathogenesis. Current Opinion in Neurology 24:3, 262-267
CrossRef28
Dustin G. James, Da Hea Seo, Jiajing Chen, Caroline Vemulapalli, Christian D. Stone. (2011) Efalizumab, a Human Monoclonal Anti-CD11a Antibody, in the Treatment of Moderate to Severe Crohn’s Disease: An Open-Label Pilot Study. Digestive Diseases and Sciences 56:6, 1806-1810
CrossRef29
Martin Duddy, Aiden Haghikia, Eleonora Cocco, Christian Eggers, Jelena Drulovic, Olga Carmona, Helene Zéphir, Ralf Gold. (2011) Managing MS in a changing treatment landscape. Journal of Neurology 258:5, 728-739
CrossRef30
EG Stefanich, DM Danilenko, H Wang, S O'Byrne, R Erickson, T Gelzleichter, H Hiraragi, H Chiu, S Ivelja, S Jeet, S Gadkari, O Hwang, F Fuh, C Looney, K Howell, V Albert, M Balazs, C Refino, S Fong, S Iyer, M Williams. (2011) A humanized monoclonal antibody targeting the β7 integrin selectively blocks intestinal homing of T lymphocytes. British Journal of Pharmacology 162:8, 1855-1870
CrossRef31
, A. Ghezzi, L. M. E. Grimaldi, M. G. Marrosu, C. Pozzilli, G. Comi, A. Bertolotto, M. Trojano, P. Gallo, R. Capra, D. Centonze, E. Millefiorini, S. Sotgiu, V. Brescia Morra, M. P. Amato, A. Lugaresi, G. Mancardi, D. Caputo, E. Montanari, L. Provinciali, L. Durelli, R. Bergamaschi, P. Bellantonio, M. R. Tola, S. Cottone, G. Savettieri, G. Tedeschi. (2011) Natalizumab therapy of multiple sclerosis: recommendations of the Multiple Sclerosis Study Group—Italian Neurological Society. Neurological Sciences 32:2, 351-358
CrossRef32
Joy Derwenskus. (2011) Current Disease-Modifying Treatment of Multiple Sclerosis. Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine 78:2, 161-175
CrossRef33
Marina Talamonti, Giulia Spallone, Alessandro Di Stefani, Antonio Costanzo, Sergio Chimenti. (2011) Efalizumab. Expert Opinion on Drug Safety 10:2, 239-251
CrossRef34
Aaron E. Miller. (2011) Multiple Sclerosis: Where Will We Be in 2020?. Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine 78:2, 268-279
CrossRef35
Cris S Constantinescu, Nasr Farooqi, Kate O'Brien, Bruno Gran. (2011) Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS). British Journal of Pharmacologyno-no
CrossRef36
Robert Weissert. (2011) Progressive multifocal leukoencephalopathy. Journal of Neuroimmunology 231:1-2, 73-77
CrossRef37
Sophia Koo, Francisco M. Marty, Lindsey R. Baden. (2011) Infectious Complications Associated with Immunomodulating Biologic Agents. Hematology/Oncology Clinics of North America 25:1, 117-138
CrossRef38
Karen Schreiber, Per Soelberg Sorensen. (2011) Cladribine in the treatment of multiple sclerosis. Clinical Investigation 1:2, 317-326
CrossRef39
Ranjan Dutta, Bruce D. Trapp. (2011) Mechanisms of neuronal dysfunction and degeneration in multiple sclerosis. Progress in Neurobiology 93:1, 1-12
CrossRef40
J. Parker, L.J. Wolansky, D. Khatry, G.P. Geba, N.A. Molfino. (2011) Brain magnetic resonance imaging in adults with asthma. Contemporary Clinical Trials 32:1, 86-89
CrossRef41
S G Kang, J Park, J Y Cho, B Ulrich, C H Kim. (2011) Complementary roles of retinoic acid and TGF-β1 in coordinated expression of mucosal integrins by T cells. Mucosal Immunology 4:1, 66-82
CrossRef42
A. Horga, M. Tintoré. (2011) Natalizumab for relapsing-remitting multiple sclerosis. Neurología (English Edition) 26:6, 357-368
CrossRef43
Eileen M. O’Connor, Rae Ann Maxwell. 2011. Clinical Development and Benefit–Risk Profile of Natalizumab. , 167-191.
CrossRef44
Tobias Boettler, Matthias von Herrath. (2010) Immunotherapy of type 1 diabetes — How to rationally prioritize combination therapies in T1D. International Immunopharmacology 10:12, 1491-1495
CrossRef45
Eilhard Mix, Hans Meyer-Rienecker, Hans-Peter Hartung, Uwe K. Zettl. (2010) Animal models of multiple sclerosis—Potentials and limitations. Progress in Neurobiology 92:3, 386-404
CrossRef46
Irini Sereti, Alison J Rodger, Martyn A French. (2010) Biomarkers in immune reconstitution inflammatory syndrome: signals from pathogenesis. Current Opinion in HIV and AIDS 5:6, 504-510
CrossRef47
Joseph R. Berger. (2010) Progressive Multifocal Leukoencephalopathy and Newer Biological Agents. Drug Safety 33:11, 969-983
CrossRef48
Michael Hutchinson. (2010) Natalizumab Therapy of Multiple Sclerosis. Journal of Interferon & Cytokine Research 30:10, 787-789
CrossRef49
A. K. Bag, J. K. Cure, P. R. Chapman, G. H. Roberson, R. Shah. (2010) JC Virus Infection of the Brain. American Journal of Neuroradiology 31:9, 1564-1576
CrossRef50
C. Tabernero García. (2010) Neurocatástrofes farmacológicas. Neurología 25, 68-79
CrossRef51
Alban Millonig, Harald Hegen, Franziska Di Pauli, Rainer Ehling, Claudia Gneiss, Martina Hoelzl, Bettina Künz, Andreas Lutterotti, Dagmar Rudzki, Thomas Berger, Markus Reindl, Florian Deisenhammer. (2010) Natalizumab treatment reduces endothelial activity in MS patients. Journal of Neuroimmunology 227:1-2, 190-194
CrossRef52
Brian G Feagan, John WD McDonald. 2010. Crohn's Disease. , 211-231.
CrossRef53
Leonid Gorelik, Michaela Lerner, Sarah Bixler, Mary Crossman, Brian Schlain, Kenneth Simon, Amy Pace, Anne Cheung, Ling Ling Chen, Melissa Berman, Fairuz Zein, Ewa Wilson, Ted Yednock, Alfred Sandrock, Susan E. Goelz, Meena Subramanyam. (2010) Anti-JC virus antibodies: Implications for PML Risk Stratification. Annals of Neurology 68:3, 295-303
CrossRef54
Ikuo Tsunoda, Robert S. Fujinami. (2010) Neuropathogenesis of Theiler’s Murine Encephalomyelitis Virus Infection, An Animal Model for Multiple Sclerosis. Journal of Neuroimmune Pharmacology 5:3, 355-369
CrossRef55
Leslie J. Marshall, Eugene O. Major. (2010) Molecular Regulation of JC Virus Tropism: Insights into Potential Therapeutic Targets for Progressive Multifocal Leukoencephalopathy. Journal of Neuroimmune Pharmacology 5:3, 404-417
CrossRef56
Yukiko Shishido-Hara. (2010) Progressive multifocal leukoencephalopathy and promyelocytic leukemia nuclear bodies: a review of clinical, neuropathological, and virological aspects of JC virus-induced demyelinating disease. Acta Neuropathologica 120:3, 403-417
CrossRef57
Anna Bellizzi, Valentina Barucca, Daniela Fioriti, Maria T. Colosimo, Monica Mischitelli, Elena Anzivino, Fernanda Chiarini, Valeria Pietropaolo. (2010) Early years of biological agents therapy in Crohn's disease and risk of the human polyomavirus JC reactivation. Journal of Cellular Physiology 224:2, 316-326
CrossRef58
Alison M. Gizinski, David A. Fox, Sujata Sarkar. (2010) Co-stimulation and T cells as therapeutic targets. Best Practice & Research Clinical Rheumatology 24:4, 463-477
CrossRef59
Doron Boltin, Alex Vilkin, Zohar Levi, Ori Elkayam, Yaron Niv. (2010) JC Virus T-Antigen DNA in Gastrointestinal Mucosa of Immunosuppressed Patients: A Prospective, Controlled Study. Digestive Diseases and Sciences 55:7, 1975-1981
CrossRef60
Tadaki Suzuki, Satoko Yamanouchi, Yuji Sunden, Yasuko Orba, Takashi Kimura, Hirofumi Sawa. (2010) Natalizumab has no direct biological effect on JC virus infectivity in permissive human neural cell lines. Journal of Medical Virology 82:7, 1229-1235
CrossRef61
Stephen J Bickston, Kishor Muniyappa. (2010) Natalizumab for the treatment of Crohn’s disease. Expert Review of Clinical Immunology 6:4, 513-519
CrossRef62
Sophia Koo, Francisco M. Marty, Lindsey R. Baden. (2010) Infectious Complications Associated with Immunomodulating Biologic Agents. Infectious Disease Clinics of North America 24:2, 285-306
CrossRef63
Reza Vosoughi, Mark S. Freedman. (2010) Therapy of MS. Clinical Neurology and Neurosurgery 112:5, 365-385
CrossRef64
Andreas P Lysandropoulos, Renaud A Du Pasquier. (2010) Demyelination as a complication of new immunomodulatory treatments. Current Opinion in Neurology 23:3, 226-233
CrossRef65
A Sami Saribaş, Ahmet Özdemir, Cathy Lam, Mahmut Safak. (2010) JC virus-induced progressive multifocal leukoencephalopathy. Future Virology 5:3, 313-323
CrossRef66
Mathias Buttmann. (2010) Treating multiple sclerosis with monoclonal antibodies: a 2010 update. Expert Review of Neurotherapeutics 10:5, 791-809
CrossRef67
Roberta Mancuso, Ambra Hernis, Rosella Cavarretta, Domenico Caputo, Elena Calabrese, Raffaello Nemni, Pasquale Ferrante, Serena Delbue, Mario Clerici. (2010) Detection of viral DNA sequences in the cerebrospinal fluid of patients with multiple sclerosis. Journal of Medical Virology 82:6, 1051-1057
CrossRef68
Maria Cristina Domingues Fink, Augusto Cesar Penalva de Oliveira, Camila Malta Romano, Jose Ernesto Vidal, Paulo Roberto Palma Urbano, Adriana Fumie Tateno, Cristina Mendes Oliveira, Expedito José de Albuquerque Luna, Claudio Sérgio Pannuti. (2010) Molecular characterization of human polyomavirus JC in Brazilian AIDS patients with and without progressive multifocal leukoencephalopathy. Journal of Clinical Virology 48:1, 6-10
CrossRef69
Chen S Tan, Igor J Koralnik. (2010) Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis. The Lancet Neurology 9:4, 425-437
CrossRef70
David B Clifford, Andrea DeLuca, David M Simpson, Gabriele Arendt, Gavin Giovannoni, Avindra Nath. (2010) Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. The Lancet Neurology 9:4, 438-446
CrossRef71
Trevor T. Hansel, Harald Kropshofer, Thomas Singer, Jane A. Mitchell, Andrew J. T. George. (2010) The safety and side effects of monoclonal antibodies. Nature Reviews Drug Discovery 9:4, 325-338
CrossRef72
Jerold Chun, Hans-Peter Hartung. (2010) Mechanism of Action of Oral Fingolimod (FTY720) in Multiple Sclerosis. Clinical Neuropharmacology 33:2, 91-101
CrossRef73
Sunita Venkateswaran, Brenda Banwell. (2010) Pediatric Multiple Sclerosis. The Neurologist 16:2, 92-105
CrossRef74
Ellen Broug, Philip A Bland-Ward, John Powell, Kevin S Johnson. (2010) Fab-arm exchange. Nature Biotechnology 28:2, 123-125
CrossRef75
Eugene O. Major. (2010) Progressive Multifocal Leukoencephalopathy in Patients on Immunomodulatory Therapies*. Annual Review of Medicine 61:1, 35-47
CrossRef76
Carlo Piccinni, Chiara Sacripanti, Elisabetta Poluzzi, Domenico Motola, Lara Magro, Ugo Moretti, Anita Conforti, Nicola Montanaro. (2010) Stronger association of drug-induced progressive multifocal leukoencephalopathy (PML) with biological immunomodulating agents. European Journal of Clinical Pharmacology 66:2, 199-206
CrossRef77
Shanika de Silva, Shane Devlin, Remo Panaccione. (2010) Optimizing the safety of biologic therapy for IBD. Nature Reviews Gastroenterology & Hepatology 7:2, 93-101
CrossRef78
B. Stankoff, A. Tourbah, Y. Taoufik, J. Gasnault. (2010) Leucoencefalopatia multifocale progressiva. EMC - Neurologia 10:3, 1-9
CrossRef79
Jillian E. Wohler, Sherry S. Smith, Scott R. Barnum. (2010)
T cells: The overlooked T-cell subset in demyelinating disease. Journal of Neuroscience Research 88:1, 1-6
CrossRef80
Masaaki Niino, Hidenao Sasaki. (2010) Update on the treatment options for multiple sclerosis. Expert Review of Clinical Immunology 6:1, 77-88
CrossRef81
Elizabeth J. Cochran. 2010. Central Nervous System. , 987-1049.
CrossRef82
Waqqas Afif, Edward V. Loftus. (2010) Safety Profile of IBD Therapeutics: Infectious Risks. Medical Clinics of North America 94:1, 115-133
CrossRef83
B.K. Kleinschmidt-DeMasters, Kenneth L. Tyler. 2010. Infections and Inflammatory Disorders. , 455-484.
CrossRef84
Waqqas Afif, Edward V. Loftus. (2009) Safety Profile of IBD Therapeutics: Infectious Risks. Gastroenterology Clinics of North America 38:4, 691-709
CrossRef85
Olaf Stüve. (2009) Knowns and unknowns in the future of multiple sclerosis treatment. Journal of the Neurological Sciences 287, S30-S36
CrossRef86
Nathalie Koning, Bernard M.J. Uitdehaag, Inge Huitinga, Robert M. Hoek. (2009) Restoring immune suppression in the multiple sclerosis brain. Progress in Neurobiology 89:4, 359-368
CrossRef87
Young-Min Hyun, Craig T. Lefort, Minsoo Kim. (2009) Leukocyte integrins and their ligand interactions. Immunologic Research 45:2-3, 195-208
CrossRef88
H.-P. Hartung, C. Warnke, R. Hohlfeld, B.C. Kieseier. (2009) Progressive multifokale Leukenzephalopathie. Der Nervenarzt 80:10, 1143-1153
CrossRef89
Chen, Yiping, Bord, Evelyn, Tompkins, Troy, Miller, Janice, Tan, Chen S., Kinkel, R. Philip, Stein, Marion C., Viscidi, Raphael P., Ngo, Long H., Koralnik, Igor J., . (2009) Asymptomatic Reactivation of JC Virus in Patients Treated with Natalizumab. New England Journal of Medicine 361:11, 1067-1074
Full Text90
Lindå, Hans, von Heijne, Anders, Major, Eugene O., Ryschkewitsch, Caroline, Berg, Johan, Olsson, Tomas, Martin, Claes, . (2009) Progressive Multifocal Leukoencephalopathy after Natalizumab Monotherapy. New England Journal of Medicine 361:11, 1081-1087
Full Text91
Wenning, Werner, Haghikia, Aiden, Laubenberger, Jörg, Clifford, David B., Behrens, Peter F., Chan, Andrew, Gold, Ralf, . (2009) Treatment of Progressive Multifocal Leukoencephalopathy Associated with Natalizumab. New England Journal of Medicine 361:11, 1075-1080
Full Text92
Melissa S. Maginnis, Walter J. Atwood. (2009) JC Virus: An oncogenic virus in animals and humans?. Seminars in Cancer Biology 19:4, 261-269
CrossRef93
Britta Siegmund, Martin Zeitz. (2009) Clinical aspects of inflammatory bowel disease. European Journal of Immunology 39:8, 2026-2030
CrossRef94
Ron Granot, Richard Lawrence, Michael Barnett, Lynette Masters, Michael Rodriguez, Con Theocharous, Roger Pamphlett, Mark Hersch. (2009) What lies beneath the tent? JC-virus cerebellar granule cell neuronopathy complicating sarcoidosis. Journal of Clinical Neuroscience 16:8, 1091-1092
CrossRef95
Aran F Labrijn, Antonio Ortiz Buijsse, Ewald T J van den Bremer, Annemiek Y W Verwilligen, Wim K Bleeker, Susan J Thorpe, Joep Killestein, Chris H Polman, Rob C Aalberse, Janine Schuurman, Jan G J van de Winkel, Paul W H I Parren. (2009) Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo. Nature Biotechnology 27:8, 767-771
CrossRef96
Kenneth R Carson, Daniele Focosi, Eugene O Major, Mario Petrini, Elizabeth A Richey, Dennis P West, Charles L Bennett. (2009) Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project. The Lancet Oncology 10:8, 816-824
CrossRef97
Mary K. Grabowski, Raphael P. Viscidi, Joseph B. Margolick, Lisa P. Jacobson, Keerti V. Shah. (2009) Investigation of pre-diagnostic virological markers for progressive multifocal leukoencephalopathy in human immunodeficiency virus-infected patients. Journal of Medical Virology 81:7, 1140-1150
CrossRef98
Alfredo Papa, Giammarco Mocci, Michele Bonizzi, Carla Felice, Gianluca Andrisani, Gianfranco Papa, Antonio Gasbarrini. (2009) Biological therapies for inflammatory bowel disease: controversies and future options. Expert Review of Clinical Pharmacology 2:4, 391-403
CrossRef99
Per Soelberg Sorensen, Svein Ivar Mellgren, Anders Svenningsson, Irina Elovaara, Jette Lautrup Frederiksen, Antonie Giaever Beiske, Kjell-Morten Myhr, Lise Vejby Søgaard, Inge Christoffer Olsen, Magnhild Sandberg-Wollheim. (2009) NORdic trial of oral Methylprednisolone as add-on therapy to Interferon beta-1a for treatment of relapsing-remitting Multiple Sclerosis (NORMIMS study): a randomised, placebo-controlled trial. The Lancet Neurology 8:6, 519-529
CrossRef100
Richard A Rudick, Chris H Polman. (2009) Current approaches to the identification and management of breakthrough disease in patients with multiple sclerosis. The Lancet Neurology 8:6, 545-559
CrossRef101
Nancy G. Wehner, Carolyn Gasper, George Shopp, Joyce Nelson, Ken Draper, Suezanne Parker, Janet Clarke. (2009) Immunotoxicity profile of natalizumab. Journal of Immunotoxicology 6:2, 115-129
CrossRef102
J.F. Rahier, S. Ben-Horin, Y. Chowers, C. Conlon, P. De Munter, G. D'Haens, E. Domènech, R. Eliakim, A. Eser, J. Frater. (2009) European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. Journal of Crohn's and Colitis 3:2, 47-91
CrossRef103
K. R. Carson, A. M. Evens, E. A. Richey, T. M. Habermann, D. Focosi, J. F. Seymour, J. Laubach, S. D. Bawn, L. I. Gordon, J. N. Winter, R. R. Furman, J. M. Vose, A. D. Zelenetz, R. Mamtani, D. W. Raisch, G. W. Dorshimer, S. T. Rosen, K. Muro, N. R. Gottardi-Littell, R. L. Talley, O. Sartor, D. Green, E. O. Major, C. L. Bennett. (2009) Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 113:20, 4834-4840
CrossRef104
Jelle L. Epker, Paula van Biezen, Paul L.A. van Daele, Teun van Gelder, Ann Vossen, Jan L.C.M. van Saase. (2009) Progressive multifocal leukoencephalopathy, a review and an extended report of five patients with different immune compromised states. European Journal of Internal Medicine 20:3, 261-267
CrossRef105
Joseph R. Berger, Sidney Houff. (2009) Opportunistic infections and other risks with newer multiple sclerosis therapies. Annals of Neurology 65:4, 367-377
CrossRef106
Ulrich Dirnagl, Kyra Becker, Andreas Meisel. (2009) Preconditioning and tolerance against cerebral ischaemia: from experimental strategies to clinical use. The Lancet Neurology 8:4, 398-412
CrossRef107
P. S. Sorensen. (2009) How effective is natalizumab as second-line treatment for multiple sclerosis in daily clinical praxis?. European Journal of Neurology 16:3, 287-288
CrossRef108
Laurie J. Barten, Douglas R. Allington, Kendra A. Procacci, Michael P. Rivey. (2009) Natalizumab update: a story of benefit and risk. Drug Discovery Today: Therapeutic Strategies 6:1, 21-31
CrossRef109
Ardith M. Courtney, Katherine Treadaway, Gina Remington, Elliot Frohman. (2009) Multiple Sclerosis. Medical Clinics of North America 93:2, 451-476
CrossRef110
Séverine Vermeire, Gert Van Assche, Paul Rutgeerts. (2009) Serum sickness, encephalitis and other complications of anti-cytokine therapy. Best Practice & Research Clinical Gastroenterology 23:1, 101-112
CrossRef111
Sylvia E Kim. (2009) Daclizumab Treatment for Multiple Sclerosis. Pharmacotherapy 29:2, 227-235
CrossRef112
A. Schröder, G. Ellrichmann, G. Chehab, M. Schneider, R.A. Linker, R. Gold. (2009) Einsatz von Rituximab in der Behandlung neuroimmunologischer Erkrankungen. Der Nervenarzt 80:2, 155-165
CrossRef113
Mengxi Jiang, Johanna R. Abend, Silas F. Johnson, Michael J. Imperiale. (2009) The role of polyomaviruses in human disease. Virology 384:2, 266-273
CrossRef114
Woojun Kim, Ho Jin Kim. (2009) Multiple Sclerosis. Journal of the Korean Medical Association 52:7, 665
CrossRef115
Florian Deisenhammer. (2009) Therapiemonitoring der Multiplen Sklerose / Therapy monitoring of multiple sclerosis. LaboratoriumsMedizin 33:1, 15-21
CrossRef116
Daniel C. Baumgart. (2009) Veto on vedolizumab (MLN0002) for Crohn's disease. Inflammatory Bowel DiseasesNA-NA
CrossRef117
David W. Brandes, Teri Callender, Ellen Lathi, Shirley O’Leary. (2009) A review of disease-modifying therapies for MS: maximizing adherence and minimizing adverse events. Current Medical Research and Opinion 25:1, 77-92
CrossRef118
Hans-Peter Hartung. (2009) New cases of progressive multifocal leukoencephalopathy after treatment with natalizumab. The Lancet Neurology 8:1, 28-31
CrossRef119
Florian Deisenhammer. (2009) Therapy monitoring of multiple sclerosis 1. LaboratoriumsMedizin 33:1, ---
CrossRef120
Dean Sheppard. 2009. Adhesion Molecules in Asthma and Airway Diseases. , 257-263.
CrossRef121
P. S. Rommer, O. Stüve, R. Goertsches, E. Mix, U. K. Zettl. (2008) Monoclonal antibodies in the therapy of multiple sclerosis. Journal of Neurology 255:S6, 28-35
CrossRef122
Olaf Stüve, Ralf Gold, Andrew Chan, Eilhard Mix, Uwe Zettl, Bernd C. Kieseier. (2008) α4-Integrin antagonism with natalizumab. Journal of Neurology 255:S6, 58-65
CrossRef123
Iván Martinez-Forero, Antonio Pelaez, Pablo Villoslada. (2008) Pharmacogenomics of multiple sclerosis: in search for a personalized therapy. Expert Opinion on Pharmacotherapy 9:17, 3053-3067
CrossRef124
Serena Delbue, Emanuela Branchetti, Renzo Boldorini, Luca Vago, Pietro Zerbi, Claudia Veggiani, Sara Tremolada, Pasquale Ferrante. (2008) Presence and expression of JCV early gene large T Antigen in the brains of immunocompromised and immunocompetent individuals. Journal of Medical Virology 80:12, 2147-2152
CrossRef125
Eilhard Mix, Hans Meyer-Rienecker, Uwe K. Zettl. (2008) Animal models of multiple sclerosis for the development and validation of novel therapies – potential and limitations. Journal of Neurology 255:S6, 7-14
CrossRef126
Olaf Stüve. (2008) The effects of natalizumab on the innate and adaptive immune system in the central nervous system. Journal of the Neurological Sciences 274:1-2, 39-41
CrossRef127
Richard J. Davenport, James R. Munday. (2008) Blocking α4-integrins — A small molecule approach to treatment of multiple sclerosis. Journal of the Neurological Sciences 274:1-2, 27-30
CrossRef128
B.K. Kleinschmidt-DeMasters, Denise M. Damek, Kevin O. Lillehei, Ahmed Dogan, Caterina Giannini. (2008) Epstein Barr Virus-Associated Primary CNS Lymphomas in Elderly Patients on Immunosuppressive Medications. Journal of Neuropathology and Experimental Neurology 67:11, 1103-1111
CrossRef129
Rocio S. Lopez-Diego, Howard L. Weiner. (2008) Novel therapeutic strategies for multiple sclerosis — a multifaceted adversary. Nature Reviews Drug Discovery 7:11, 909-925
CrossRef130
Marinella Clerico, Chiara Rivoiro, Giulia Contessa, Daniela Viglietti, Luca Durelli. (2008) The therapy of multiple sclerosis with immune-modulating or immunosuppressive drug. Clinical Neurology and Neurosurgery 110:9, 878-885
CrossRef131
Ralf A. Linker, Bernd C. Kieseier, Ralf Gold. (2008) Identification and development of new therapeutics for multiple sclerosis. Trends in Pharmacological Sciences 29:11, 558-565
CrossRef132
Christian K. Schneider, Gabriele Schäffner-Dallmann. (2008) Typical pitfalls in applications for marketing authorization of biotechnological products in Europe. Nature Reviews Drug Discovery 7:11, 893-899
CrossRef133
Eliza F. Chakravarty. (2008) Viral infection and reactivation in autoimmune disease. Arthritis & Rheumatism 58:10, 2949-2957
CrossRef134
Georgina Perez-Liz, Luis Del Valle, Antonio Gentilella, Sidney Croul, Kamel Khalili. (2008) Detection of JC virus DNA fragments but not proteins in normal brain tissue. Annals of Neurology 64:4, 379-387
CrossRef135
Marinos C Dalakas. (2008) B cells as therapeutic targets in autoimmune neurological disorders. Nature Clinical Practice Neurology 4:10, 557-567
CrossRef136
R.A. Linker, B.C. Kieseier. (2008) Therapieentscheidungen bei Multipler Sklerose. Der Nervenarzt 79:10, 1123-1134
CrossRef137
Benjamin M Segal, Cris S Constantinescu, Aparna Raychaudhuri, Lilianne Kim, Rosanne Fidelus-Gort, Lloyd H Kasper. (2008) Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study. The Lancet Neurology 7:9, 796-804
CrossRef138
Dirk Reske, Walter F Haupt. (2008) Use of rituximab in multiple sclerosis: current progress and future perspectives. Expert Review of Clinical Immunology 4:5, 573-582
CrossRef139
Gian Luigi Mancardi, Maria Pia Amato, Roberto D’Alessandro, Filippo Drago, Clara Milanese, Patrizia Popoli, Leandro Provinciali, Pasqualino Rossi, Giovanni Savettieri, Gioacchino Tedeschi, Maria Rosaria Tola, Nicola Vanacore, Anna Covezzoli, Marisa Rosa, Carlo Piccinni, Nicola Montanaro, Laura Periotto, Antonio Addis, Nello Martini. (2008) Natalizumab: a country-based surveillance program. Neurological Sciences 29:S2, 235-237
CrossRef140
Harold Moses, David W. Brandes. (2008) Managing adverse effects of disease-modifying agents used for treatment of multiple sclerosis. Current Medical Research and Opinion 24:9, 2679-2690
CrossRef141
J. D. Isaacs. (2008) Therapeutic T-cell manipulation in rheumatoid arthritis: past, present and future. Rheumatology 47:10, 1461-1468
CrossRef142
Thomas Weber. (2008) Progressive Multifocal Leukoencephalopathy. Neurologic Clinics 26:3, 833-854
CrossRef143
Elizabeth A. Hartman, DeRen Huang. (2008) Update on PML: Lessons from the HIV uninfected and new insights in pathogenesis and treatment. Current HIV/AIDS Reports 5:3, 112-119
CrossRef144
Carolina Ciumas, Alexandra Montavont, Philippe Ryvlin. (2008) Magnetic resonance imaging in clinical trials. Current Opinion in Neurology 24:4, 431-436
CrossRef145
Aran F Labrijn, Rob C Aalberse, Janine Schuurman. (2008) When binding is enough: nonactivating antibody formats. Current Opinion in Immunology 20:4, 479-485
CrossRef146
Gouri Chatterjee, Lisette M. Carrithers, Michael D. Carrithers. (2008) Epithelial V-like antigen regulates permeability of the blood–CSF barrier. Biochemical and Biophysical Research Communications 372:3, 412-417
CrossRef147
Laurent Peyrin-Biroulet, Pierre Desreumaux, William J Sandborn, Jean-Frédéric Colombel. (2008) Crohn's disease: beyond antagonists of tumour necrosis factor. The Lancet 372:9632, 67-81
CrossRef148
C. Kneitz, H. Wiendl. (2008) Progressive multifokale Leukoenzephalopathie bei rheumatologischen Erkrankungen. Zeitschrift für Rheumatologie 67:4, 290-294
CrossRef149
Bruce D. Trapp, Klaus-Armin Nave. (2008) Multiple Sclerosis: An Immune or Neurodegenerative Disorder?. Annual Review of Neuroscience 31:1, 247-269
CrossRef150
Tracy DeAngelis, Fred Lublin. (2008) Multiple sclerosis: new treatment trials and emerging therapeutic targets. Current Opinion in Neurology 21:3, 261-271
CrossRef151
Phillip G. Popovich, Erin E. Longbrake. (2008) Can the immune system be harnessed to repair the CNS?. Nature Reviews Neuroscience 9:6, 481-493
CrossRef152
Matteo Pelosini, Daniele Focosi, Fazzi Rita, Sara Galimberti, Francesco Caracciolo, Edoardo Benedetti, Federico Papineschi, Mario Petrini. (2008) Progressive multifocal leukoencephalopathy: report of three cases in HIV-negative hematological patients and review of literature. Annals of Hematology 87:5, 405-412
CrossRef153
Allen J. Aksamit. (2008) Progressive multifocal leukoencephalopathy. Current Treatment Options in Neurology 10:3, 178-185
CrossRef154
Arthur Kaser, Herbert Tilg. (2008) Novel therapeutic targets in the treatment of IBD. Expert Opinion on Therapeutic Targets 12:5, 553-563
CrossRef155
Mathias Buttmann, Peter Rieckmann. (2008) Treating multiple sclerosis with monoclonal antibodies. Expert Review of Neurotherapeutics 8:3, 433-455
CrossRef156
Silvio Danese, Erika Angelucci, Alberto Malesci, Renzo Caprilli. (2008) Biological agents for ulcerative colitis: Hypes and hopes. Medicinal Research Reviews 28:2, 201-218
CrossRef157
B.A. O’Hara, W.J. Atwood. (2008) Interferon β1-a and selective anti-5HT2a receptor antagonists inhibit infection of human glial cells by JC virus. Virus Research 132:1-2, 97-103
CrossRef158
Tracy DeAngelis, Fred Lublin. (2008) Neurotherapeutics in multiple sclerosis: Novel agents and emerging treatment strategies. Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine 75:2, 157-167
CrossRef159
Michel Vierboom, Elia Breedveld, Ivanela Kondova, Bert A 't Hart. (2008) The significance of non-human primates as preclinical models of human arthritic disease. Expert Opinion on Drug Discovery 3:3, 299-310
CrossRef160
Aaron Boster, Gilles Edan, Elliott Frohman, Adil Javed, Olaf Stuve, Alexandros Tselis, Howard Weiner, Bianca Weinstock-Guttman, Omar Khan. (2008) Intense immunosuppression in patients with rapidly worsening multiple sclerosis: treatment guidelines for the clinician. The Lancet Neurology 7:2, 173-183
CrossRef161
Raija L.P. Lindberg, Lutz Achtnichts, Francine Hoffmann, Jens Kuhle, Ludwig Kappos. (2008) Natalizumab alters transcriptional expression profiles of blood cell subpopulations of multiple sclerosis patients. Journal of Neuroimmunology 194:1-2, 153-164
CrossRef162
Marylou V. Solbrig, Anton N. Hasso, Cheryl A. Jay. (2008) CNS Viruses—Diagnostic Approach. Neuroimaging Clinics of North America 18:1, 1-18
CrossRef163
Simona Bonavita, Renata Conforti, Antonio Russo, Rosaria Sacco, Alessandro Tessitore, Antonio Gallo, Marida Corte, Maria Rosaria Monsurrò, Gioacchino Tedeschi. (2008) Infratentorial progressive multifocal leukoencephalopathy in a patient treated with fludarabine and rituximab. Neurological Sciences 29:1, 37-39
CrossRef164
Andrew B Grossman, Robert N Baldassano. (2008) Specific considerations in the treatment of pediatric inflammatory bowel disease. Expert Review of Gastroenterology & Hepatology 2:1, 105-124
CrossRef165
Majda M. Thurnher, Pia C. Sundgren. (2008) Imaging of Slow Viruses. Neuroimaging Clinics of North America 18:1, 133-148
CrossRef166
Yuhong Yang, Anne R. Gocke, Amy Lovett-Racke, Paul D. Drew, Michael K. Racke. (2008) PPAR Alpha Regulation of the Immune Response and Autoimmune Encephalomyelitis. PPAR Research 2008, 1-6
CrossRef167
Yvette Leung, Remo Panaccione. (2008) Anti-Adhesion Molecule Strategies for Crohn Disease. BioDrugs 22:4, 259-264
CrossRef168
Ray Gani, Gavin Giovannoni, David Bates, Belinda Kemball, Steve Hughes, John Kerrigan. (2008) Cost-Effectiveness Analyses of Natalizumab (Tysabri®) Compared with Other Disease-Modifying Therapies for People with Highly Active Relapsing-Remitting Multiple Sclerosis in the UK. PharmacoEconomics 26:7, 617-627
CrossRef169
E. Gibbs, H. Tremlett, N. Ball, S. Hashimoto. (2008) Malignant melanoma in a multiple sclerosis patient with persistent neutralizing antibodies to interferon-beta. European Journal of Neurology 15:1, e4-e4
CrossRef170
Dimitrios Vassilopoulos, Leonard H Calabrese. (2007) Risks of immunosuppressive therapies including biologic agents in patients with rheumatic diseases and co-existing chronic viral infections. Current Opinion in Rheumatology 19:6, 619-625
CrossRef171
C. Kleinschnitz, S. G. Meuth, O. Stüve, B. Kieseier, H. Wiendl. (2007) Multiple sclerosis therapy: An update on recently finished trials. Journal of Neurology 254:11, 1473-1490
CrossRef172
Joseph R. Berger. (2007) Progressive multifocal leukoencephalopathy. Current Neurology and Neuroscience Reports 7:6, 461-469
CrossRef173
Hin Hin Ko, Brian Bressler. (2007) Natalizumab: pharmacology, clinical efficacy and safety in the treatment of patients with Crohn’s disease. Expert Review of Gastroenterology & Hepatology 1:1, 29-39
CrossRef174
Vissia Viglietta, Samia J. Khoury. (2007) Modulating co-stimulation. Neurotherapeutics 4:4, 666-675
CrossRef175
Seymour Katz. (2007) “Mind the Gap”. Journal of Clinical Gastroenterology 41:9, 799-809
CrossRef176
Bettina Kuenz, Florian Deisenhammer, Thomas Berger, Markus Reindl. (2007) Diagnostic biomarkers in multiple sclerosis. Expert Opinion on Medical Diagnostics 1:2, 225-233
CrossRef177
Wendi Zhou, Madeva Sharma, Joy Martinez, Tumul Srivastava, Don J. Diamond, Wendy Knowles, Simon F. Lacey. (2007) Functional Characterization of BK Virus-Specific CD4 + T Cells with Cytotoxic Potential in Seropositive Adults. Viral Immunology 20:3, 379-388
CrossRef178
Kate Manley, Gretchen V. Gee, Carl P. Simkevich, John M. Sedivy, Walter J. Atwood. (2007) Microarray analysis of glial cells resistant to JCV infection suggests a correlation between viral infection and inflammatory cytokine gene expression. Virology 366:2, 394-404
CrossRef179
Hans-Ullrich Völker, Klaus Kraft, Eva Arnold, Silke Steinhoff, Georgios Kolios, Stephanie Sommer. (2007) Progressive multifocal leukoencephalopathy developing in advanced pulmonal sarcoidosis. Clinical Neurology and Neurosurgery 109:7, 624-630
CrossRef180
Stuart D. Cook. (2007) Approved drugs and their problems in patient care: Routes of administration and dosing. Journal of the Neurological Sciences 259:1-2, 38-41
CrossRef181
C Janneke van der Woude, Daniel W Hommes. (2007) Biologics in Crohn's disease: searching indicators for outcome. Expert Opinion on Biological Therapy 7:8, 1233-1243
CrossRef182
C. Kleinschnitz, S.G. Meuth, B.C. Kieseier, H. Wiendl. (2007) Multiple-Sklerose-Update zur Pathophysiologie und neuen immuntherapeutischen Ansätzen. Der Nervenarzt 78:8, 883-911
CrossRef183
Leonard H. Calabrese, Eamonn S. Molloy, DeRen Huang, Richard M. Ransohoff. (2007) Progressive multifocal leukoencephalopathy in rheumatic diseases: Evolving clinical and pathologic patterns of disease. Arthritis & Rheumatism 56:7, 2116-2128
CrossRef184
Kenneth P. Johnson. (2007) Natalizumab (Tysabri) Treatment for Relapsing Multiple Sclerosis. The Neurologist 13:4, 182-187
CrossRef185
Michael D. Carrithers, Lisette M. Carrithers, Jan Czyzyk, Octavian Henegariu. (2007) Characterization of a severe parenchymal phenotype of experimental autoimmune encephalomyelitis in (C57BL6xB10.PL)F1 mice. Journal of Neuroimmunology 187:1-2, 31-43
CrossRef186
Alessandro Lavagna, Massimiliano Bergallo, Marco Daperno, Raffaello Sostegni, Cristina Costa, Rosalia Leto, Lucia Crocellà, Giancarlo Molinaro, Rodolfo Rocca, Rossana Cavallo, Angelo Pera. (2007) Infliximab and the risk of latent viruses reactivation in active Crohn's disease. Inflammatory Bowel Diseases 13:7, 896-902
CrossRef187
DeRen Huang, Michael Cossoy, Meizhang Li, Dean Choi, Alan Taege, Susan M. Staugaitis, Susan Rehm, Richard M. Ransohoff. (2007) Inflammatory progressive multifocal leukoencephalopathy in human immunodeficiency virus-negative patients. Annals of Neurology 62:1, 34-39
CrossRef188
Michael Clark, Jean-Frederic Colombel, Brian C. Feagan, Richard N. Fedorak, Stephen B. Hanauer, Michael A. Kamm, Lloyd Mayer, Carol Regueiro, Paul Rutgeerts, William J. Sandborn, Bruce E. Sands, Stefan Schreiber, Stephan Targan, Simon Travis, Severine Vermeire. (2007) American Gastroenterological Association Consensus Development Conference on the Use of Biologics in the Treatment of Inflammatory Bowel Disease, June 21–23, 2006. Gastroenterology 133:1, 312-339
CrossRef189
Ransohoff, Richard M., . (2007) Natalizumab for Multiple Sclerosis. New England Journal of Medicine 356:25, 2622-2629
Full Text190
William H. Stuart. (2007) Combination therapy for the treatment of multiple sclerosis: challenges and opportunities. Current Medical Research and Opinion 23:6, 1199-1208
CrossRef191
Brian G. Feagan. (2007) Medical Management of Ulcerative Colitis in 2006: What's on the Horizon?. The American Journal of Gastroenterology 102:s1, S7-S13
CrossRef192
Mark A. Kroenke, Benjamin M. Segal. (2007) Th17 and Th1 responses directed against the immunizing epitope, as opposed to secondary epitopes, dominate the autoimmune repertoire during relapses of experimental autoimmune encephalomyelitis. Journal of Neuroscience Research 85:8, 1685-1693
CrossRef193
Fiona Costello, Olaf Stüve, Martin S Weber, Scott S Zamvil, Elliot Frohman. (2007) Combination therapies for multiple sclerosis: scientific rationale, clinical trials, and clinical practice. Current Opinion in Neurology 20:3, 281-285
CrossRef194
Daniel C. Bullard, Xianzhen Hu, Jillian E. Adams, Trenton R. Schoeb, Scott R. Barnum. (2007) p150/95 (CD11c/CD18) Expression Is Required for the Development of Experimental Autoimmune Encephalomyelitis. The American Journal of Pathology 170:6, 2001-2008
CrossRef195
F. Tarantini, I. Baiardini, G. Passalacqua, F. Braido, G. W. Canonica. (2007) Asthma treatment: ?magic bullets which seek their own targets?. Allergy 62:6, 605-610
CrossRef196
Bernd C Kieseier, Heinz Wiendl, Bernhard Hemmer, Hans-Peter Hartung. (2007) Treatment and treatment trials in multiple sclerosis. Current Opinion in Neurology 20:3, 286-293
CrossRef197
Wojciech Blonski, Gary R. Lichtenstein. (2007) Safety of biologic therapy. Inflammatory Bowel Diseases 13:6, 769-796
CrossRef198
A. M. O’Rourke, E. Y. Wang, L. Salter-Cid, L. Huang, A. Miller, E. Podar, H. F. Gao, D. S. Jones, M. D. Linnik. (2007) Benefit of inhibiting SSAO in relapsing experimental autoimmune encephalomyelitis. Journal of Neural Transmission 114:6, 845-849
CrossRef199
Simon F Lacey, Wendi Zhou. (2007) Immune responses to BK and JC viruses in immunocompromised patients. Future Virology 2:3, 255-266
CrossRef200
Adrienn Angyal, József Prechl, Gabriella Sármay. (2007) Possible therapeutic applications of single-chain antibodies in systemic autoimmune diseases. Expert Opinion on Biological Therapy 7:5, 691-704
CrossRef201
Ludwig Kappos, David Bates, Hans-Peter Hartung, Eva Havrdova, David Miller, Chris H Polman, Mads Ravnborg, Stephen L Hauser, Richard A Rudick, Howard L Weiner, Paul W O'Connor, John King, Ernst Wilhelm Radue, Tarek Yousry, Eugene O Major, David B Clifford. (2007) Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring. The Lancet Neurology 6:5, 431-441
CrossRef202
Stephan R. Targan, Brian G. Feagan, Richard N. Fedorak, Bret A. Lashner, Remo Panaccione, Daniel H. Present, Martina E. Spehlmann, Paul J. Rutgeerts, Zsolt Tulassay, Miroslava Volfova, Douglas C. Wolf, Chito Hernandez, Jeffrey Bornstein, William J. Sandborn. (2007) Natalizumab for the Treatment of Active Crohn’s Disease: Results of the ENCORE Trial. Gastroenterology 132:5, 1672-1683
CrossRef203
Michel P.M. Vierboom, Margreet Jonker, Paul P. Tak, Bert A. ’t Hart. (2007) Preclinical models of arthritic disease in non-human primates. Drug Discovery Today 12:7-8, 327-335
CrossRef204
Michael Hutchinson. (2007) Natalizumab: A new treatment for relapsing remitting multiple sclerosis. Therapeutics and Clinical Risk Management 3:2, 259-268
CrossRef205
Adam Szczuciński, Jacek Losy. (2007) Chemokines and chemokine receptors in multiple sclerosis. Potential targets for new therapies. Acta Neurologica Scandinavica 115:3, 137-146
CrossRef206
Olaf Stüve, Jeffrey L. Bennett. (2007) Pharmacological Properties, Toxicology and Scientific Rationale for the use of Natalizumab (Tysabri
CrossRef207
Mathias Buttmann, Peter Rieckmann. (2007) Interferon-β 1b in multiple sclerosis. Expert Review of Neurotherapeutics 7:3, 227-239
CrossRef208
Gert van Assche. (2007) Emerging drugs to treat Crohn’s disease. Expert Opinion on Emerging Drugs 12:1, 49-59
CrossRef209
Motohisa Yamamoto, Hiroki Takahashi, Hideki Wakasugi, Yasutaka Sukawa, Mayuko Saito, Chisako Suzuki, Yasuyoshi Naishiro, Hiroyuki Yamamoto, Yasuhisa Shinomura, Kohzoh Imai. (2007) Leukoencephalopathy during administration of etanercept for refractory rheumatoid arthritis. Modern Rheumatology 17:1, 72-74
CrossRef210
Jeffrey S Hyams, David C Wilson, Adrian Thomas, Robert Heuschkel, Sally Mitton, Brent Mitchell, Regina Daniels, Michele A Libonati, Susan Zanker, Subra Kugathasan. (2007) Natalizumab Therapy for Moderate to Severe Crohn Disease in Adolescents. Journal of Pediatric Gastroenterology and Nutrition 44:2, 185-191
CrossRef211
R. Álvarez-Lafuente, M. García-Montojo, V. De Las Heras, M. Bartolomé, R. Arroyo. (2007) Interferon-beta treatment and active replication of the JC virus in relapsing-remitting multiple sclerosis patients. European Journal of Neurology 14:2, 233-236
CrossRef212
Roberta Mancuso, Serena Delbue, Elisa Borghi, Elisabetta Pagani, Maria Gaetana Calvo, Domenico Caputo, Enrico Granieri, Pasquale Ferrante. (2007) Increased prevalence of varicella zoster virus DNA in cerebrospinal fluid from patients with multiple sclerosis. Journal of Medical Virology 79:2, 192-199
CrossRef213
John K MacDonald, John WD McDonald, John K MacDonald. 2007. Natalizumab for induction of remission in Crohn's disease. .
CrossRef214
Bernd C Kieseier, Heinz Wiendl. (2007) Oral Disease-Modifying Treatments for Multiple Sclerosis. CNS Drugs 21:6, 483-502
CrossRef215
J.A. Stockman. (2007) Progressive Multifocal Leukoencephalopathy Complicating Treatment With Natalizumab and Interferon Beta-1a for Multiple Sclerosis. Yearbook of Pediatrics 2007, 356-358
CrossRef216
Eric H Liu, Richard M Siegel, David M Harlan, John J O'Shea. (2007) T cell–directed therapies: lessons learned and future prospects. Nature Immunology 8:1, 25-30
CrossRef217
Bruce E. Sands, Richard Kozarek, Jack Spainhour, Charles F. Barish, Scott Becker, Lawrence Goldberg, Seymour Katz, Ronald Goldblum, Rena Harrigan, Deborah Hilton, Stephen B. Hanauer. (2007) Safety and tolerability of concurrent natalizumab treatment for patients with Crohn's disease not in remission while receiving infliximab. Inflammatory Bowel Diseases 13:1, 2-11
CrossRef218
Paul O’Connor. (2007) Natalizumab and the role of α 4 -integrin antagonism in the treatment of multiple sclerosis. Expert Opinion on Biological Therapy 7:1, 123-136
CrossRef219
B.K. Kleinschmidt-DeMasters. (2007) SOCIETY NEWS. Brain Pathology 17:1, 122-127
CrossRef220
Istvan Pirko, John H. Noseworthy. 2007. Demyelinating Disorders of the Central Nervous System. , 1103-1133.
CrossRef221
Jung Han Yoon, Oh Young Bang, Ho Sung Kim. (2007) Progressive Multifocal Leukoencephalopathy in AIDS: Proton MR Spectroscopy Patterns of Asynchronous Lesions Confirmed by Serial Diffusion-Weighted Imaging and Apparent Diffusion Coefficient Mapping. Journal of Clinical Neurology 3:4, 200
CrossRef222
Ikuo Tsunoda, Emily Jane Terry, Benjamin J. Marble, Elias Lazarides, Catherine Woods, Robert S. Fujinami. (2007) Modulation of Experimental Autoimmune Encephalomyelitis by VLA-2 Blockade. Brain Pathology 17:1, 45-55
CrossRef223
Gauree Gupta, Ebbing Lautenbach, James D. Lewis. (2006) Incidence and Risk Factors for Herpes Zoster Among Patients With Inflammatory Bowel Disease. Clinical Gastroenterology and Hepatology 4:12, 1483-1490
CrossRef224
Jagadeshwar G. Reddy, Edward V. Loftus. (2006) Safety of Infliximab and Other Biologic Agents in the Inflammatory Bowel Diseases. Gastroenterology Clinics of North America 35:4, 837-855
CrossRef225
B. Salzberger. (2006) Antivirale Therapie. Der Internist 47:12, 1245-1250
CrossRef226
Gert Van Assche, Séverine Vermeire, Paul Rutgeerts. (2006) Focus on Mechanisms of Inflammation in Inflammatory Bowel Disease Sites of Inhibition: Current and Future Therapies. Gastroenterology Clinics of North America 35:4, 743-756
CrossRef227
Lesley Ann Saketkoo, Luis R. Espinoza. (2006) Impact of Biologic Agents on Infectious Diseases. Infectious Disease Clinics of North America 20:4, 931-961
CrossRef228
Hans Link, Yu-Min Huang. (2006) Oligoclonal bands in multiple sclerosis cerebrospinal fluid: An update on methodology and clinical usefulness. Journal of Neuroimmunology 180:1-2, 17-28
CrossRef229
Robert Weissert. (2006) The curtain is drawn for both natalizumab and fingolimod (FTY720): a new era of multiple sclerosis therapy has arrived. Expert Review of Neurotherapeutics 6:11, 1587-1590
CrossRef230
Allen J. Aksamit. (2006) Review of Progressive Multifocal Leukoencephalopathy and Natalizumab. The Neurologist 12:6, 293-298
CrossRef231
Stephen B. Hanauer. (2006) Clinical trials report. Current Gastroenterology Reports 8:6, 467-469
CrossRef232
Geert D’Haens, Marco Daperno. (2006) Advances in biologic therapy for ulcerative colitis and Crohn’s disease. Current Gastroenterology Reports 8:6, 506-512
CrossRef233
Paulus Mrass, Wolfgang Weninger. (2006) Immune cell migration as a means to control immune privilege: lessons from the CNS and tumors. Immunological Reviews 213:1, 195-212
CrossRef234
Peter Vanderslice, Darren G Woodside. (2006) Integrin antagonists as therapeutics for inflammatory diseases. Expert Opinion on Investigational Drugs 15:10, 1235-1255
CrossRef235
William A. Faubion, Athos Bousvaros. (2006) Medical Therapy for Refractory Pediatric Crohn’s Disease. Clinical Gastroenterology and Hepatology 4:10, 1199-1213
CrossRef236
Veerasamy Ravichandran, Eugene O. Major. (2006) Viral proteomics: A promising approach for understanding JC virus tropism. PROTEOMICS 6:20, 5628-5636
CrossRef237
Bernd C Kieseier, Heinz Wiendl, Hans-Peter Hartung. (2006) The inflamed peripheral nervous system: update on immune therapies. Current Opinion in Neurology 19:5, 433-436
CrossRef238
Arnaud Charil, Tarek A Yousry, Marco Rovaris, Frederik Barkhof, Nicola De Stefano, Franz Fazekas, David H Miller, Xavier Montalban, Jack H Simon, Chris Polman, Massimo Filippi. (2006) MRI and the diagnosis of multiple sclerosis: expanding the concept of “no better explanation”. The Lancet Neurology 5:10, 841-852
CrossRef239
William W. Agace. (2006) Tissue-tropic effector T cells: generation and targeting opportunities. Nature Reviews Immunology 6:9, 682-692
CrossRef240
Jean Frédéric Colombel, Laurent Peyrin-Biroulet. (2006) Natalizumab: a promising treatment for Crohn’s disease. Expert Review of Clinical Immunology 2:5, 677-689
CrossRef241
Yi-Yang Yvonne Li, H Daniel Perez, Thomas M Zollner. (2006) Fatalities in natalizumab treatment - a 'no go for leukocyte recirculation approaches?. Expert Opinion on Therapeutic Targets 10:4, 489-499
CrossRef242
Igor J. Koralnik. (2006) Progressive multifocal leukoencephalopathy revisited: Has the disease outgrown its name?. Annals of Neurology 60:2, 162-173
CrossRef243
James S.W. Kong, Suzanne S. Teuber, M. Eric Gershwin. (2006) Potential adverse events with biologic response modifiers. Autoimmunity Reviews 5:7, 471-485
CrossRef244
Akira Goto, Yoshiaki Arimura, Yasuhisa Shinomura, Kohzoh Imai, Yuji Hinoda. (2006) Antisense Therapy of MAdCAM-1 for Trinitrobenzenesulfonic Acid-Induced Murine Colitis. Inflammatory Bowel Diseases 12:8, 758-765
CrossRef245
Russell E Bartt. (2006) Multiple sclerosis, natalizumab therapy, and progressive multifocal leukoencephalopathy. Current Opinion in Neurology 19:4, 341-349
CrossRef246
JK MacDonald, JWD McDonald, John MacDonald. 2006. Natalizumab for induction of remission in Crohn's disease. .
CrossRef247
Gert Van Assche, S??verine Vermeire, Paul Rutgeerts. (2006) Safety issues with biological therapies for inflammatory bowel disease. Current Opinion in Gastroenterology 22:4, 370???376
CrossRef248
Jean Sibilia. (2006) Les biothérapies immunomodulatrices: Une révolution thérapeutique dans les maladies auto-immunes. Revue Francophone des Laboratoires 2006:384, 34-39
CrossRef249
Renaud A. Du Pasquier, Marion C. Stein, Marco A. Lima, Xin Dang, Jims Jean-Jacques, Yue Zheng, Norman L. Letvin, Igor J. Koralnik. (2006) JC virus induces a vigorous CD8+ cytotoxic T cell response in multiple sclerosis patients. Journal of Neuroimmunology 176:1-2, 181-186
CrossRef250
Jean Klastersky. (2006) Adverse effects of the humanized antibodies used as cancer therapeutics. Current Opinion in Oncology 18:4, 316-320
CrossRef251
Wojciech Blonski, Gary R. Lichtenstein. (2006) Safety of biologics in inflammatory bowel disease. Current Treatment Options in Gastroenterology 9:3, 221-233
CrossRef252
Bernhard Hemmer, Eiliot Frohman, Hans Peter Hartung, Olaf Stüve. (2006) Central nervous system infections – a potential complication of systemic immunotherapy. Current Opinion in Neurology 19:3, 271-276
CrossRef253
Paulo Fontoura, Lawrence Steinman, Ariel Miller. (2006) Emerging therapeutic targets in multiple sclerosis. Current Opinion in Neurology 19:3, 260-266
CrossRef254
Masaaki Niino, Caroline Bodner, Marie-Lune Simard, Sudabeh Alatab, Dawn Gano, Ho Jin Kim, Manuela Trigueiro, Denise Racicot, Christine Guérette, Jack P. Antel, Alyson Fournier, Francois Grand'Maison, Amit Bar-Or. (2006) Natalizumab effects on immune cell responses in multiple sclerosis. Annals of Neurology 59:5, 748-754
CrossRef255
Francesco Lolli, Paolo Rovero, Mario Chelli, Anna Maria Papini. (2006) Toward biomarkers in multiple sclerosis: new advances. Expert Review of Neurotherapeutics 6:5, 781-794
CrossRef256
Sandeep K Agarwal, Michael B Brenner. (2006) Role of adhesion molecules in synovial inflammation. Current Opinion in Rheumatology 18:3, 268-276
CrossRef257
Olaf Stüve, Christina M. Marra, Keith R. Jerome, Linda Cook, Petra D. Cravens, Sabine Cepok, Elliot M. Frohman, J. Theodore Phillips, Gabriele Arendt, Bernhard Hemmer, Nancy L. Monson, Michael K. Racke. (2006) Immune surveillance in multiple sclerosis patients treated with natalizumab. Annals of Neurology 59:5, 743-747
CrossRef258
Annette Langer-Gould, Lawrence Steinman. (2006) Progressive multifocal leukoencephalopathy and multiple sclerosis: Lessons from natalizumab. Current Neurology and Neuroscience Reports 6:3, 253-258
CrossRef259
B. Engelhardt. (2006) Molecular mechanisms involved in T cell migration across the blood–brain barrier. Journal of Neural Transmission 113:4, 477-485
CrossRef260
Dorothée Chabas, Ari J. Green, Emmanuelle Waubant. (2006) Pediatric multiple sclerosis. NeuroRX 3:2, 264-275
CrossRef261
S. Vermeire, P. Rutgeerts. (2006) The changing face of treatment for Crohn's disease. British Journal of Surgery 93:4, 385-386
CrossRef262
Joseph R. Berger, Sidney Houff. (2006) Progressive multifocal leukoencephalopathy: lessons from AIDS and natalizumab. Neurological Research 28:3, 299-305
CrossRef263
Jeffrey L. Bennett. (2006) Natalizumab and progressive multifocal leukoencephalopathy: migrating towards safe adhesion molecule therapy in multiple sclerosis. Neurological Research 28:3, 291-298
CrossRef264
Elizabeth R. Gore. (2006) Immune Function Tests for Hazard Identification: A Paradigm Shift in Drug Development. Basic <html_ent glyph="@amp;" ascii="&"/> Clinical Pharmacology <html_ent glyph="@amp;" ascii="&"/> Toxicology 98:4, 331-335
CrossRef265
Polman, Chris H., O'Connor, Paul W., Havrdova, Eva, Hutchinson, Michael, Kappos, Ludwig, Miller, David H., Phillips, J. Theodore, Lublin, Fred D., Giovannoni, Gavin, Wajgt, Andrzej, Toal, Martin, Lynn, Frances, Panzara, Michael A., Sandrock, Alfred W., . (2006) A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis. New England Journal of Medicine 354:9, 899-910
Full Text266
Rudick, Richard A., Stuart, William H., Calabresi, Peter A., Confavreux, Christian, Galetta, Steven L., Radue, Ernst-Wilhelm, Lublin, Fred D., Weinstock-Guttman, Bianca, Wynn, Daniel R., Lynn, Frances, Panzara, Michael A., Sandrock, Alfred W., . (2006) Natalizumab plus Interferon Beta-1a for Relapsing Multiple Sclerosis. New England Journal of Medicine 354:9, 911-923
Full Text267
Yousry, Tarek A., Major, Eugene O., Ryschkewitsch, Caroline, Fahle, Gary, Fischer, Steven, Hou, Jean, Curfman, Blanche, Miszkiel, Katherine, Mueller-Lenke, Nicole, Sanchez, Esther, Barkhof, Frederik, Radue, Ernst-Wilhelm, Jäger, Hans R., Clifford, David B., . (2006) Evaluation of Patients Treated with Natalizumab for Progressive Multifocal Leukoencephalopathy. New England Journal of Medicine 354:9, 924-933
Full Text268
Frohman, Elliot M., Racke, Michael K., Raine, Cedric S., . (2006) Multiple Sclerosis — The Plaque and Its Pathogenesis. New England Journal of Medicine 354:9, 942-955
Full Text269
Ropper, Allan H., . (2006) Selective Treatment of Multiple Sclerosis. New England Journal of Medicine 354:9, 965-967
Full Text270
Joshua R. Korzenik, Daniel K. Podolsky. (2006) Evolving knowledge and therapy of inflammatory bowel disease. Nature Reviews Drug Discovery 5:3, 197-209
CrossRef271
Dean M Wingerchuk. (2006) Multiple sclerosis disease-modifying therapies: adverse effect surveillance and management. Expert Review of Neurotherapeutics 6:3, 333-346
CrossRef272
Carl Nathan. (2006) Neutrophils and immunity: challenges and opportunities. Nature Reviews Immunology 6:3, 173-182
CrossRef273
Annette Langer-Gould, Lawrence Steinman. (2006) What went wrong in the natalizumab trials?. The Lancet 367:9512, 708-710
CrossRef274
Sunanda Kane. (2006) ANOTHER BIOLOGIC THERAPY FOR CROHN DISEASE: NOT SO FAST. Evidence-Based Gastroenterology 7:1, 5-6
CrossRef275
Christine Savage, E. William St. Clair. (2006) New Therapeutics in Rheumatoid Arthritis. Rheumatic Disease Clinics of North America 32:1, 57-74
CrossRef276
Gretchen V. Gee, Aisling S. Dugan, Natia Tsomaia, Dale F. Mierke, Walter J. Atwood. (2006) The role of sialic acid in human polyomavirus infections. Glycoconjugate Journal 23:1-2, 19-26
CrossRef277
Bernd C Kieseier, Heinz Wiendl. (2006) Multiple sclerosis: advances, excitements, disenchantments. The Lancet Neurology 5:1, 2-3
CrossRef278
Kirsten Schaffer, Noreen Sheehy, Suzie Coughlan, Colm Bergin, William W Hall. (2006) JC virus in the Irish population: Significant increase of genotype 2 in immunocompromised individuals. Journal of Neurovirology 12:1, 39-46
CrossRef279
Wojciech Blonski, Gary R Lichtenstein. (2006) Complications of biological therapy for inflammatory bowel diseases. Current Opinion in Gastroenterology 22:1, 30-43
CrossRef280
Britta Engelhardt. (2006) Immune cell migration across the blood–brain barrier: molecular mechanisms and therapeutic targeting. Future Neurology 1:1, 47-56
CrossRef281
Francesco Lanzarotto, Marta Carpani, Rakesh Chaudhary, Subrata Ghosh. (2006) Novel Treatment Options for Inflammatory Bowel Disease. Drugs 66:9, 1179-1189
CrossRef282
Jonathan C. P. Roos, Andrew J. K. Ostor. (2006) Anti–tumor necrosis factor α therapy and the risk of JC virus infection. Arthritis & Rheumatism 54:1, 381-382
CrossRef283
David Pleasure, Athena Soulika, Sunit K. Singh, Vittorio Gallo, Peter Bannerman. (2006) Inflammation in white matter: Clinical and pathophysiological aspects. Mental Retardation and Developmental Disabilities Research Reviews 12:2, 141-146
CrossRef284
Dorothée Chabas, Ari J. Green, Emmanuelle Waubant. (2006) Pediatric multiple sclerosis. Neurotherapeutics 3:2, 264
CrossRef285
Brian W Behm, Stephen J Bickston. (2006) Medical management of Crohn's disease: current therapy and recent advances. Expert Review of Clinical Immunology 2:1, 109-120
CrossRef286
R SERGOTT. (2006) Progressive Multifocal Leukoencephalopathy Complicating Treatment With Natalizumab and Interferon Beta-1a for Multiple SclerosisKleinschmidt-DeMasters BK, Tyler KL (Univ of Colorado, Denver; Denver Veterans Affairs Med Ctr) N Engl J Med 353:369–374, 2005§. Yearbook of Ophthalmology 2006, 187-188
CrossRef287
A VERMA. (2006) Progressive Multifocal Leukoencephalopathy Complicating Treatment With Natalizumab and Interferon Beta-1a for Multiple SclerosisKleinschmidt-DeMasters BK, Tyler KL (Univ of Colorado, Denver; Denver Veterans Affairs Med Ctr) N Engl J Med 353:369–374, 2005§. Yearbook of Neurology and Neurosurgery 2006, 70-72
CrossRef288
David C. Metz, Nimish Vakil, Emmet B. Keeffe, Gary R. Lichtenstein. (2005) Advances in Gastrointestinal Pharmacotherapy. Clinical Gastroenterology and Hepatology 3:12, 1167-1179
CrossRef289
Podolsky, Daniel K., . (2005) Selective Adhesion-Molecule Therapy and Inflammatory Bowel Disease — A Tale of Janus?. New England Journal of Medicine 353:18, 1965-1968
Full Text290
Sandborn, William J., Colombel, Jean Frédéric, Enns, Roberts, Feagan, Brian G., Hanauer, Stephen B., Lawrance, Ian C., Panaccione, Remo, Sanders, Martin, Schreiber, Stefan, Targan, Stephan, van Deventer, Sander, Goldblum, Ronald, Despain, Darrin, Hogge, Gary S., Rutgeerts, Paul, . (2005) Natalizumab Induction and Maintenance Therapy for Crohn's Disease. New England Journal of Medicine 353:18, 1912-1925
Full Text291
Reinhard Hohlfeld, Hartmut Wekerle. (2005) Drug Insight: using monoclonal antibodies to treat multiple sclerosis. Nature Clinical Practice Neurology 1:1, 34-44
CrossRef292
Laurence J. Egan, William J. Sandborn. (2005) Positioning novel biologic, probiotic, and apheresis therapies for crohn’s disease and ulcerative colitis. Current Gastroenterology Reports 7:6, 485-491
CrossRef293
Marco Lima, Igor Koralnik. (2005) New features of progressive multifocal leukoencephalopathy in the era of highly active antiretroviral therapy and natalizumab. Journal of NeuroVirology 11:0, 52-57
CrossRef294
(2005) Progressive Multifocal Leukoencephalopathy, Natalizumab, and Multiple Sclerosis. New England Journal of Medicine 353:16, 1744-1746
Full Text295
Norman J Kachuck. (2005) Challenges and opportunities: what we are learning from the clinical natalizumab experience. Expert Review of Neurotherapeutics 5:5, 605-615
CrossRef296
Orly Avitzur. (2005) NEUROLOGISTS MAKE SPORTS AND FITNESS PART OF WORK AND PLAY. Neurology Today 5:9, 40-42
CrossRef297
Mark T Muir, Amy E Lovett-Racke, Michael K Racke. (2005) Novel therapeutic strategies targeting the pathogenic T-cells in multiple sclerosis. Expert Review of Clinical Immunology 1:3, 345-355
CrossRef298
Kurt Samson. (2005) DESPITE COMPLICATIONS, ‘PRELIMINARY STEPS’ UNDERWAY TO RESTART NATALIZUMAB TRIALS. Neurology Today 5:9, 31-33
CrossRef299
Edward V. Loftus. (2005) Inflammatory Bowel Disease Extending Its Reach. Gastroenterology 129:3, 1117-1120
CrossRef300
Britta Engelhardt, Richard M. Ransohoff. (2005) The ins and outs of T-lymphocyte trafficking to the CNS: anatomical sites and molecular mechanisms. Trends in Immunology 26:9, 485-495
CrossRef301
Berger, Joseph R., Koralnik, Igor J., . (2005) Progressive Multifocal Leukoencephalopathy and Natalizumab — Unforeseen Consequences. New England Journal of Medicine 353:4, 414-416
Full Text302
Van Assche, Gert, Van Ranst, Marc, Sciot, Raf, Dubois, Bénédicte, Vermeire, Séverine, Noman, Maja, Verbeeck, Jannick, Geboes, Karel, Robberecht, Wim, Rutgeerts, Paul, . (2005) Progressive Multifocal Leukoencephalopathy after Natalizumab Therapy for Crohn's Disease. New England Journal of Medicine 353:4, 362-368
Full Text303
Langer-Gould, Annette, Atlas, Scott W., Green, Ari J., Bollen, Andrew W., Pelletier, Daniel, . (2005) Progressive Multifocal Leukoencephalopathy in a Patient Treated with Natalizumab. New England Journal of Medicine 353:4, 375-381
Full Text304
Adelman, Burt, Sandrock, Alfred, Panzara, Michael A., . (2005) Natalizumab and Progressive Multifocal Leukoencephalopathy. New England Journal of Medicine 353:4, 432-433
Full Text305
Drazen, Jeffrey M., . (2005) Patients at Risk. New England Journal of Medicine 353:4, 417-417
Full Text306
William A Sheremata, Alireza Minagar, J Steven Alexander, Timothy Vollmer. (2005) The Role of Alpha-4 Integrin in the Aetiology of Multiple Sclerosis. CNS Drugs 19:11, 909-922
CrossRef
- Letters
